ERBB2 and triple-negative breast carcinoma: Triple-negative breast cancers (TNBC) are “aggressive” and highly malignant tumors characterized by the lack of expression of estrogen-, progesterone-, and epidermal growth factor type 2 (HER2) receptors, thereby being poorly responsive to hormonal therapies and to HER2-targeting drugs.